Publications by authors named "V Divino"
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation.
Expert Rev Pharmacoecon Outcomes Res
January 2025
Introduction: The 2022 Inflation Reduction Act is expected to result in lower drug prices for Medicare beneficiaries in the United States (US). The Centers for Medicare & Medicaid Services (CMS) released the most recent draft guidance for the medicare drug price negotiation (DPN) program in May 2024.
Areas Covered: In August 2023, the list of 10 drugs selected for the DPN were published and the first round of negotiations are now complete.
Article Synopsis
- Gout is a painful form of arthritis that can lead to more severe health issues when not properly treated; Pegloticase is a drug used to treat patients who do not respond to standard gout treatments.
- A study analyzed data from over 400 patients with chronic uncontrolled gout and found that their condition worsened significantly in the two years leading up to starting pegloticase therapy, with increases in gout-related symptoms and healthcare usage.
- The findings suggest that identifying and treating patients sooner could help reduce the complications and healthcare needs associated with uncontrolled gout.
Background And Aims: Real-world analyses on burden of illness in patients with alpha-1 antitrypsin deficiency (AATD) are limited. We investigated the real-world burden of liver-related clinical events among adult and pediatric patients with AATD in the USA.
Methods: This was a retrospective, observational analysis of administrative claims data from the IQVIA PharMetrics Plus and Ambulatory Electronic Medical Records databases from 2011 to 2022.
To evaluate all-cause and liver-associated healthcare resource utilization (HCRU) and costs among patients with alpha-1 antitrypsin deficiency (AATD) with liver disease (LD) and/or lung disease (LgD). This was a retrospective analysis of linked administrative claims data from the IQVIA PharMetrics Plus and the IQVIA Ambulatory Electronic Medical Records (AEMR) databases from 1 July 2021 to 31 January 2022. Patients with AATD in the IQVIA PharMetrics Plus database were included with ≥1 inpatient or ≥2 outpatient medical claims ≥90 days apart with a diagnosis of AATD, or with records indicating a protease inhibitor (Pi)*ZZ/Pi*MZ genotype in the IQVIA AEMR database with linkage to IQVIA PharMetrics Plus.
View Article and Find Full Text PDFIntroduction: In people with type 2 diabetes (PwT2D) who also have obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. The objective of this study was to explore the relationship between glycemic control and obesity among PwT2D in Europe and Australia using recent real-world data and applying consistent methodology across countries.
Methods: Retrospective study utilizing IQVIA electronic medical records (EMR) databases grouped into panels based on specialty of contributing physicians.